Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Trial watch: Immunostimulatory cytokines in cancer therapy.

Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 3;3:e29030. eCollection 2014.

PMID:
25083328
[PubMed]
Free PMC Article
2.

Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.

Srivastava N, McDermott D.

Cancer Manag Res. 2014 Jun 20;6:279-89. doi: 10.2147/CMAR.S64979. eCollection 2014. Review.

PMID:
25018651
[PubMed]
Free PMC Article
3.

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.

Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr.

J Immunother Cancer. 2014 May 13;2:11. doi: 10.1186/2051-1426-2-11. eCollection 2014. Review.

PMID:
24971166
[PubMed]
Free PMC Article
4.

Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review).

Malas S, Harrasser M, Lacy KE, Karagiannis SN.

Oncol Rep. 2014 Jun 20. doi: 10.3892/or.2014.3275. [Epub ahead of print]

PMID:
24969320
[PubMed - as supplied by publisher]
Free PMC Article
5.

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.

Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P.

J Immunother Cancer. 2014 May 14;2:14. doi: 10.1186/2051-1426-2-14. eCollection 2014. Review.

PMID:
24883190
[PubMed]
Free PMC Article
6.

Sarcoma immunotherapy: past approaches and future directions.

D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD.

Sarcoma. 2014;2014:391967. doi: 10.1155/2014/391967. Epub 2014 Mar 20. Review.

PMID:
24778572
[PubMed]
Free PMC Article
7.

Cutaneous melanoma: new advances in treatment.

Foletto MC, Haas SE.

An Bras Dermatol. 2014 Mar-Apr;89(2):301-10.

PMID:
24770508
[PubMed - in process]
Free PMC Article
8.

Pathways and therapeutic targets in melanoma.

Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE.

Oncotarget. 2014 Apr 15;5(7):1701-52.

PMID:
24743024
[PubMed - in process]
Free PMC Article
9.

BRAF and beyond: Tailoring strategies for the individual melanoma patient.

Jarkowski A 3rd, Khushalani NI.

J Carcinog. 2014 Feb 7;13:1. doi: 10.4103/1477-3163.126759. eCollection 2014. Review.

PMID:
24737949
[PubMed]
Free PMC Article
10.

γδ T cells for cancer immunotherapy: A systematic review of clinical trials.

Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J.

Oncoimmunology. 2014 Jan 1;3(1):e27572. Epub 2014 Jan 17. Review.

PMID:
24734216
[PubMed]
Free PMC Article
11.

Dabrafenib for treatment of BRAF-mutant melanoma.

Kainthla R, Kim KB, Falchook GS.

Pharmgenomics Pers Med. 2013 Dec 31;7:21-9. doi: 10.2147/PGPM.S37220. eCollection 2014. Review.

PMID:
24516336
[PubMed]
Free PMC Article
12.

Metastatic melanoma - a review of current and future drugs.

Velho TR.

Drugs Context. 2012 Nov 19;2012:212242. doi: 10.7573/dic.212242. eCollection 2012 Nov 19. Review.

PMID:
24432031
[PubMed]
Free PMC Article
13.

High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines.

Dillman RO, Depriest C, McClure SE.

Cancer Biother Radiopharm. 2014 Mar;29(2):53-7. doi: 10.1089/cbr.2013.1565. Epub 2013 Dec 31.

PMID:
24380630
[PubMed - in process]
Free PMC Article
14.

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L.

J Clin Invest. 2014 Jan 2;124(1):99-110.

PMID:
24292706
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Systemic therapy of non-resectable metastatic melanoma.

Orouji A, Goerdt S, Utikal J.

Cancers (Basel). 2010 May 26;2(2):955-69. doi: 10.3390/cancers2020955.

PMID:
24281101
[PubMed]
Free PMC Article
16.

Biologics in dermatology.

Chandler D, Bewley A.

Pharmaceuticals (Basel). 2013 Apr 17;6(4):557-78. doi: 10.3390/ph6040557.

PMID:
24276125
[PubMed]
Free PMC Article
17.

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.

Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R.

Front Immunol. 2013 Nov 8;4:363. doi: 10.3389/fimmu.2013.00363. eCollection 2013. Review.

PMID:
24265631
[PubMed]
Free PMC Article
18.

Cytokines in cancer immunotherapy.

Lee S, Margolin K.

Cancers (Basel). 2011 Oct 13;3(4):3856-93. doi: 10.3390/cancers3043856.

PMID:
24213115
[PubMed]
Free PMC Article
19.

Clinical outcome of 31 patients with primary malignant melanoma of the vagina.

Huang Q, Huang H, Wan T, Deng T, Liu J.

J Gynecol Oncol. 2013 Oct;24(4):330-5. doi: 10.3802/jgo.2013.24.4.330. Epub 2013 Oct 2.

PMID:
24167668
[PubMed]
Free PMC Article
20.

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?

Swarbrick A, Junankar SR, Batten M.

Oncoimmunology. 2013 Aug 1;2(8):e25409. Epub 2013 Jul 1.

PMID:
24083081
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk